Glimepiride

# Glimepiride ## Overview Glimepiride is a second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells. It is used as an adjunct to diet and exercise for glycemic control in type 2 diabetes mellitus. ## Primary Indications - Type 2 diabetes mellitus (monotherapy or combination with metformin, thiazolidinediones, or insulin) - Not indicated for type 1 diabetes or diabetic ketoacidosis ## Adult Dosing - **Initial dose:** 1–2 mg once daily with breakfast or first main meal. - **Titration:** Increase by 1–2 mg every 1–2 weeks based on glycemic response. - **Usual maintenance:** 1–4 mg once daily. - **Maximum dose:** 8 mg once daily. - Dosing above 8 mg is not recommended (no additional benefit and increased hypoglycemia risk). ## Pediatric Dosing - **Not established:** Safety and efficacy in pediatric patients (<18 years) have not been determined. Use is not recommended. ## Dose Adjustments - **Renal impairment:** Use with caution; start at 1 mg once daily. Avoid in severe renal impairment (eGFR <30 mL/min) or dialysis. - **Hepatic impairment:** Start at 1 mg once daily; titrate slowly. Avoid in severe hepatic impairment. - **Transition from other insulin secretagogues:** Consider starting at lower doses; exact protocol depends on local guidance. ## Contraindications - Hypersensitivity to glimepiride or sulfonamides (risk of cross-allergy) - Type 1 diabetes mellitus - Diabetic ketoacidosis - Severe renal or hepatic impairment - Pregnancy (except for certain protocols; local guidelines apply) ## Adverse Effects - **Most common:** Hypoglycemia, particularly in elderly, irregular eating, renal/hepatic impairment. - **Other:** Weight gain, nausea, dizziness, headache. - **Rare but serious:** Hemolytic anemia (G6PD deficiency), severe hypoglycemia, hepatitis, cholestatic jaundice. - Hypoglycemia symptoms may be masked by beta-blockers. ## Key Drug Interactions - **Enhanced hypoglycemic effect:** Insulin, other antidiabetics, MAOIs, NSAIDs, salicylates, sulfonamides, alcohol. - **Reduced hypoglycemic effect:** Thiazide diuretics, corticosteroids, beta-agonists, oral contraceptives, thyroid products. - **Increased glimepiride exposure:** Fluconazole, miconazole (azole antifungals), gemfibrozil. - **Warfarin:** May enhance anticoagulant effect (monitor INR). ## Monitoring - **Glycemic control:** Fasting and postprandial glucose, HbA1c (every 3–6 months). - **Hypoglycemia:** Symptoms, especially in elderly or those with renal/hepatic impairment. - **Renal/hepatic function:** Baseline and periodically; adjust dose as needed. - **CBC:** If signs of anemia or infection (rare hemolytic anemia). ## Clinical Pearls - Dosing is best timed with meals to reduce hypoglycemia risk. - Initiate at lowest possible dose in elderly (e.g., 1 mg daily). - Glimepiride is less likely to cause severe hypoglycemia than glyburide? (Caveat: Evidence varies; clinical judgment needed.) - Not recommended for use during pregnancy; insulin is preferred. - Ensure patient carries glucose source and understands sick-day rules. *This information is for educational purposes. Always verify current prescribing information and local protocols before clinical use.*